EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example

Jens-Uwe Peter iD, Peter Dieudonné, Oliver Zolk iD

Pharmaceuticals · 08.04.2024 · 17 (4) · 473

DOI: 10.3390/ph17040473 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 08.04.2024. Verfasst von Jens-Uwe Peter und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, Immanuel Klinik Rüdersdorf, Brandenburg Medical School, 15562 Rüdersdorf, Germany. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brandenburg Medical School publication fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Midazolam, a short-acting benzodiazepine, is widely used to alleviate patient anxiety, enhance compliance, and aid in anesthesia. While its side effects are typically dose-dependent and manageable with vigilant perioperative monitoring, serious cardiorespiratory complications, including fatalities and permanent neurological impairment, have been documented. Prolonged exposure to benzodiazepines, such as midazolam, has been associated with neurological changes in infants. Despite attempts to employ therapeutic drug monitoring for optimal sedation dosing, its efficacy has been limited. Consequently, efforts are underway to identify alternative predictive markers to guide individualized dosing and mitigate adverse effects. Understanding these factors is crucial for determining midazolam’s suitability for future administration, particularly after a severe adverse reaction. This article aims to elucidate the factors influencing midazolam’s pharmacokinetics and pharmacodynamics, potentially leading to adverse events. Finally, a case study is presented to exemplify the complex investigation into the causative factors of midazolam-related adverse events.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reactionbiomarkersdrug therapy optimizationmidazolampersonalized medicinepharmacodynamicspharmacogenomicspharmacokineticstherapeutic drug monitoring

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, Immanuel Klinik Rüdersdorf, Brandenburg Medical School, 15562 Rüdersdorf, Germany.
  • Department of Anesthesiology, University Hospital Ulm, 89081 Ulm, Germany.

ORCID-Profile: Jens-Uwe Peter, Oliver Zolk

Förderung

  • Brandenburg Medical School publication fund

Zitieren

APA

Peter, J. U., Dieudonné, P., & Zolk, O. (2024). Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example. Pharmaceuticals, 17(4), 473. https://doi.org/10.3390/ph17040473

Vancouver

Peter JU, Dieudonné P, Zolk O. Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example. Pharmaceuticals. 2024;17(4):473. doi:10.3390/ph17040473

BibTeX
@article{Peter2024,
  author = {Peter, Jens-Uwe and Dieudonné, Peter and Zolk, Oliver},
  title = {Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {4},
  pages = {473},
  doi = {10.3390/ph17040473}
}
Kostenlos starten →